The impact of future technology on cancer care

Clinical Medicine

Volumn 2, Issue 6, 2002, Pages 560-568

  Sikora, Karol ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Biomarkers; Cancer; Chemoprevention; Chemotherapy; Surrogate endpoints

Indexed keywords

BEAM THERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER PATIENT; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER SURGERY; COMPUTER SYSTEM; CONFERENCE PAPER; ECONOMIC ASPECT; FUTUROLOGY; HEALTH CARE DELIVERY; HEALTH CARE FINANCING; HEALTH CARE SYSTEM; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEDICAL ETHICS; MEDICAL INFORMATION SYSTEM; MINIMALLY INVASIVE SURGERY; MOLECULAR GENETICS; MORALITY; PATIENT ATTITUDE; PATIENT REFERRAL; RISK ASSESSMENT; SOCIAL ASPECT; SOCIETY; TECHNOLOGY;

EID: 0036864524     PISSN: 14702118     EISSN: None     Source Type: Journal    
DOI: 10.7861/clinmedicine.2-6-560     Document Type: Conference Paper

References (23)

1. Sikora K. Developing a global strategy for cancer. Eur J Cancer 1999; 35:24-31.
2. Sikora S and Sikora K. Wealth and cancer. Cancer Strategy 2001;1:56-64.
3. Taylor P. The Smoke Ring - The Politics of Tobacco. London: Bodley Head, 1984.
4. Greenwald P. Clifford CK. Milner JA. Diet and cancer prevention. Eur J Cancer 2001;37:948-65.
5. Pisani P, Parkin M, Munoz N and Ferlay J. Cancer and infection. Cancer Epidemiology, Biomarkers and Prevention 1999;6:387-400.
6. Schlag PM. Hunerbein M. Minimal access surgery for cancer treatment. Onkologie 2002;25:72-3.
7. Sikora K. Radiotherapy for cancer treatment. In Price P and Sikora K (eds) Treatment of Cancer. London: Hodder, 2002.
8. The use of nitrogen mustard for the treatment of lymphoma. J Am Med Assn, 1945.
9. Garrett M and Workman P. Discovering novel chemotherapeutic drugs for the third millennium. Eur J Cancer 1999;35:2010-30.
10. Robinson D, Wu Y and Lin S. The protein tyrosine kinase family of the human genome. Oncogene 2000;19:5548-57.
11. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-5.
12. Workman P, Clarke P. Innovative cancer drug targets: Genomics, transcriptomics and clinomics. Expert Opin Pharmacother 2001;2:911-5.
13. Somberg JC. Biomarkers and surrogate endpoints. Am J Ther 1999;4:179-80.
14. Buyse M, Thirion P, Carlson RW, Burzykowski T et al. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: A meta-analysis. Meta-Analysis Group in Cancer. Lancet 2000;356:373-8.
15. Kupelian PA, Buchsbaum JC, Patel C, Elshaikh M et al. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. Int J Radiation Oncol Biol Physics 2002;52:704-11.
16. Phelps M. PET: The merging of biology and imaging into molecular imaging. J Nucl Med 2000;41:661-81.
17. Wang SC, Zhang L, Hortobagyi GN, Hung MC. Targeting HER2: Recent developments and future directions for breast cancer patients. Semin Oncol 2001;28(6) (Suppl 18):21-9.
18. Druker B, Talpaz M, Resta D, Peng B et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia. N Eng J Med 2001;344:1031-7.
19. Kipps TJ. Advances in classification and therapy of indolent B-cell malignancies. Semin Oncol 2002:29;(1) (Suppl):298-104.
20. Watanabe T, Wu T, Catalano P et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. New Eng J Med 2001;344:1196-206.
21. Evans W, Relling M. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 1999;286:487-91.
22. Simon R, Freidlin B, Rubinstein L, Arbuck SG et al. Accelerated titration designs for phase I trials in oncology. J Nat Cancer Inst 1997;89:1138-44.
23. Buolamwini J. Cell cycle molecular targets in novel anticancer drug discovery. Curr Pharm Res 2000;6:379-92.